Bold DECISION makes Nexavar a new standard in thyroid cancer
This article was originally published in Scrip
Executive Summary
Bayer Healthcare and Onyx Pharmaceuticals' multi-kinase inhibitor Nexavar (sorafenib) is a new standard of care for progressive radioactive iodine-refractory differentiated thyroid cancer, say experts upon the publication of pivotal data supporting its use in this setting.